“We developed the immunosignature technology primarily for early detection of disease, but realized it may have other applications,”
Scientists from the Center for Innovations in Medicine in the Biodesign Institute at Arizona State University have developed a comprehensive, microchip-based technology, called immunosignature diagnosis, which can rapidly and comprehensively measure an individual’s vaccine response, promising to take much of the initial guesswork out of predicting effective vaccines.
Professor Stephen Albert Johnston and Joseph Barten Legutki, used a mouse model of influenza infection to determine how the immunosignature of a natural infection can be used to discriminate between a protective and non-protective vaccine. The study appears in the October 28 early online edition of the Proceedings of the National Academy of Sciences.
Johnston is driven by the quest to develop disruptive technology that could make health care more effective and affordable. Despite 17 percent of the U.S. GDP tied to health care costs and growing, the U.S. does not get as much value per dollar as other countries (spending the most per capita yet ranking last in efficiency). He believes innovative diagnostic technologies that could determine whether or not an individual would get sick before symptoms appear, as well as the early identification of microbial culprits of infections has high potential for transforming medicine.
“We developed the immunosignature technology primarily for early detection of disease, but realized it may have other applications,” said Johnston, who directs the Center for Innovations and Medicine at the Biodesign Institute “In this work we demonstrate that it may also be useful for screening candidate vaccines.”
Currently, the effectiveness of vaccines is evaluated by looking for the presence a particular type of antibody from the vaccine-generated immune response or by extensive and complicated sets of analyses. The power of the immunosignature is that this effectiveness can be completed in one fell swoop, by using thousands of random molecules aligned on a microscope slide, like the transistors on a computer chip.
“We use an array of 10,000 short peptides, each one about twenty amino acids long, to generate a high degree of specificity and sensitivity for measuring both human, dog, and mouse infections and chronic and genetic diseases,” said Legutki, a faculty in CIM and lead author of the paper. “A subset of these peptides will stand out, based on an individual’s antibody repertoire, and provide a unique pattern, or signature for a given disease.”
In the study, they used a mouse H1N1 flu model system. This included both seasonal forms of influenza or inactive control, as well as several commercially available vaccines that could provide full or partial protection, and asked whether or not the immunosignature could predict vaccine effectiveness. They also examined individual differences among those receiving the same vaccine, and whether the immunosignature profile could have the power to reveal what parts of influenza virus were doing the most harm.
They found that the live and inactive forms of the virus produced different immunosignatures, with different intensities of immune response, yet both contained a core immunosignature of the virus.
Go deeper with Bing News on:
- ASU jumps to top 10 in global patent rankingson June 6, 2019 at 4:32 am
Among the 130 patents awarded to ASU in 2018 are technologies for flexible batteries, an immunosignature-based diagnosis of cancer in dogs and a handheld device that can read your metabolism on the ...
- HealthTell Announces Receipt of an NIH/NCI Grant to Detect the Presence of Brain Canceron December 2, 2014 at 12:00 am
to evaluate the performance of the company's proprietary Immunosignature™ Technology in accurately diagnosing brain cancer. This will include the specific diagnosis of glioblastoma multiforme (GBM), ...
- Early Warning of Any Canceron July 24, 2014 at 9:48 am
In an article entitled, “Immunosignature system for diagnosis of cancer,” the researchers describe how their system can meet at least one of their self-imposed requirements—universality. This article, ...
- Cancer Diagnosis: New Technique Promises Accurate and Early Detectionon July 15, 2014 at 3:20 am
The immunosignature technique offers a superior alternative ... Looking at the array, an accurate diagnosis can be made. Using 20 samples, each from five cancer patient groups, along with 20 ...
- New technology shows promise in taking the guesswork out of vaccine developmenton October 27, 2013 at 5:00 pm
Scientists from the Center for Innovations in Medicine in the Biodesign Institute at Arizona State University have developed a comprehensive, microchip-based technology, called immunosignature ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Areaon January 12, 2020 at 11:28 am
and chikungunya antibody program have de-risked its prophylactic vaccines and systemic therapeutics modalities. As a result, Moderna intends to bring new development candidates forward within these ...
- We May Be One Step Closer To Potential Dementia Vaccineon January 12, 2020 at 4:19 am
Alzheimers is a devastating diagnosis for people suffering from the disease, as well as their families, but a group of researchers feels that they are one step closer to finding a cure. Alzheimer's ...
- Therapeutic & Preventive Vaccine Market Study, 2019-2025 - Analysis by Type, End-user and Regionon January 10, 2020 at 4:01 pm
The "Global Therapeutic and Preventive Vaccine Market 2019-2025" report has been added to ResearchAndMarkets.com's offering.
- A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different cladeson January 10, 2020 at 4:08 am
In conclusion, we have developed two VSV-based vaccine candidates, VSV-EBOV-HAfl and VSV-HAfl, that provide proof-of-concept for rapid protection against HPAI virus infection that are mediating ...
- Rejuvenating the BCG Vaccineon January 10, 2020 at 2:18 am
However, they did not believe that it would arrest further disease development. The vaccine in the blood causes a T cell population to form in the lungs, which can quickly eliminate the tubercle ...